

Appendix 4D

Preliminary financial statements for the half-year ended 31 December 2022

as required by ASX listing rule 4.2A

1. Company details

Name of entity:	Clarity Pharmaceuticals Ltd
ABN:	36 143 005 341
Reporting period:	Half Year ended 31 December 2022
Previous period:	Half Year ended 31 December 2021

2. Results for announcement to the market

				\$'000
Revenue from ordinary activities	up	0%	to	0
Loss from ordinary activities after tax attributable to the owners of Clarity Pharmaceuticals Ltd	down	18%	to	(11,243)
Loss for the year attributable to the owners of Clarity Pharmaceuticals Ltd	down	18%	to	(11,243)

Dividends

There were no dividends paid, recommended, or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$11,242,655.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' Report and the consolidated financial statements for the half-year ended 31 December 2022.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	31.5	39.5

Appendix 4D

Preliminary financial statements for the half-year ended 31 December 2022

as required by ASX listing rule 4.2A

4. Control gained over entities

Not applicable

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

7. Audit qualification or review

Details of audit/review dispute or qualification (if any):

This report is based on the consolidated financial statements for the half-year ended 31 December 2022 which have been reviewed by Grant Thornton who have issued an unmodified opinion.

8. Attachments

Details of attachments (if any):

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' Report and the consolidated financial statements for the half-year ended 31 December 2022.

This information should be read in conjunction with the 2022 Annual Report.

9. Signed

As authorised by the Board of Directors



Robert Vickery
Company Secretary
28 February 2023